TNFSF13 and plasma cell myeloma: Examples include bispecific CAR-T cells designed for B cell lymphoma/leukemia and A proliferation-inducing ligand (APRIL)-based CAR-T cells simultaneously targeting both BCMA and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) in multiple myeloma (48, 49).